Publication: Intramyocardial angiogenic cell precursors in nonischemic dilated cardiomyopathy
Issued Date
2009-12-01
Resource Type
ISSN
02184923
Other identifier(s)
2-s2.0-70350709767
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Cardiovascular and Thoracic Annals. Vol.17, No.4 (2009), 382-388
Suggested Citation
Kitipan V. Arom, Permyos Ruengsakulrach, Michael Belkin, Montip Tiensuwan Intramyocardial angiogenic cell precursors in nonischemic dilated cardiomyopathy. Asian Cardiovascular and Thoracic Annals. Vol.17, No.4 (2009), 382-388. doi:10.1177/0218492309338105 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/27846
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Intramyocardial angiogenic cell precursors in nonischemic dilated cardiomyopathy
Other Contributor(s)
Abstract
To determine the efficacy of intramyocardial injection of angiogenic cell precursors in nonischemic dilated cardiomyopathy, 35 patients with nonischemic dilated cardiomyopathy underwent injections of angiogenic cell precursors into the left ventricle (cell group). Seventeen patients with nonischemic dilated cardiomyopathy were matched from the heart failure database to form a control group that was treated medically. Angiogenic cell precursors were obtained from autologous blood, cultured in vitro, and injected into all free-wall areas of the left ventricle in the cell group. After these injections, New York Heart Association functional class improved significantly by 1.1 ± 0.7 classes at 284.7 ± 136.2 days, and left ventricular ejection fraction improved in 71.4% of patients (25/35); the mean increase in left ventricular ejection fraction was 4.4% ± 10.6% at 192.7 ± 135.1 days. Improved quality of life was demonstrated by better physical function, role-physical, general health, and vitality domains in a short-form health survey at the 3-month follow-up. In the control group, there were no significant improvements in left ventricular ejection fraction or New York Heart Association class which increased by 0.6 ± 0.8 classes. It was concluded that intramyocardial angiogenic cell precursor injection is probably effective in the treatment of nonischemic dilated cardiomyopathy. Disclosures and Freedom of Investigation Professor Michael Belkin is an advisory board member, a minor shareholder, and receives a consulting fee from TheraVitae Co. Ltd. However, the authors had full control of the study, methods used, outcome measurements, data analysis, and production of the written report. © SAGE Publications 2009.